Replimune (REPL) Stock: Biotech Shares Surge 100% on Regulatory Breakthrough

TLDR FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline for the drug’s approval Replimune stock doubled on Monday, rising 100% to $9.00 per share in late-session trading The resubmission followed a complete response letter [...]

The post Replimune (REPL) Stock: Biotech Shares Surge 100% on Regulatory Breakthrough appeared first on Blockonomi.